Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Vallari Shah, Amy L. Sherborne, David C. Johnson, Sidra Ellis, Amy Price, Farzana Chowdhury, Jack Kendall, Matthew Jenner, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Gareth J. Morgan, Faith E. Davies, Gordon Cook, David A. Cairns, Richard S. Houlston, Graham Jackson, Martin Kaiser
Abstract
The prognosis for newly diagnosed multiple myeloma (NDMM) has improved with the advent of new agents, but outcome in some patients remains very poor. Identifying patients with high-risk disease early opens up the prospect of stratified treatment
Topics & Concepts
Multiple myelomaMultiplex ligation-dependent probe amplificationInternal medicineFluorescence in situ hybridizationOncologyMedicineMultiplexTransplantationBioinformaticsBiologyGeneGeneticsChromosomeExonMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsCancer Mechanisms and Therapy